FMP

FMP

Enter

ZTS - Zoetis Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ZTS.png

Zoetis Inc.

ZTS

NYSE

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

153.47 USD

1.17 (0.762%)

Latest ZTS News

Danny Green

Feb 12, 2025

Zoetis Inc. (NYSE:ZTS) Earnings Preview: Key Financial Insights

Zoetis Inc. (NYSE:ZTS) is a leading global animal health company, specializing in the discovery, development, and manufacturing of veterinary vaccines and medicines. As a key player in the animal health industry, Zoetis competes with companies like Elanco Animal Health and Merck Animal Health. The company is set to release its quarterly earnings on February 13, 2025, before the market opens. Wall Street analysts estimate Zoetis's earnings per share (EPS) to be $1.37, with projected revenues of ...

Read More

Seeking Alpha

Aug 15, 2024

The Highest Quality Dividend-Growth Healthcare Stocks

Quality Snapshots evaluate dividend-growth companies based on five quality factors including financial performance, resilience and dividend safety. This healthcare sector overview identifies 26 top quality stocks in the sector. Johnson & Johnson and Zoetis discussed as high-quality, fairly valued healthcare stocks with very different yields and growth rates.

Read More

MarketBeat

Aug 13, 2024

Which Pet Stock Should Get Your Tail Wagging in 2024?

It's not a sector as red-hot as artificial intelligence, but pet stocks warrant investor attention in 2024. According to PetExec, U.S. households spend over $136 billion per year on their pets.

Read More

Zacks Investment Research

Aug 7, 2024

Zoetis (ZTS) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Zoetis (ZTS) could be a good stock pick from a technical perspective. ZTS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Read More

Zacks Investment Research

Aug 7, 2024

Zoetis (ZTS) Just Reclaimed the 200-Day Moving Average

From a technical perspective, Zoetis (ZTS) is looking like an interesting pick, as it just reached a key level of support. ZTS recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Read More

Zacks Investment Research

Aug 7, 2024

Zoetis (ZTS) Just Overtook the 50-Day Moving Average

Zoetis (ZTS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ZTS broke out above the 50-day moving average, suggesting a short-term bullish trend.

Read More

Seeking Alpha

Aug 7, 2024

Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)

Zoetis stock price increased by 8.6% since last publication, underperforming S&P 500 index. Company raised full-year guidance, expecting double-digit growth, driven by DTC strategy and new products. Upgraded rating to 'Buy' with $210 target price per share, expecting revenue growth and margin expansion.

Read More

Zacks Investment Research

Aug 6, 2024

Zoetis (ZTS) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More

Investopedia

Aug 6, 2024

Zoetis Raises Guidance on Revenue Growth

Zoetis (ZTS) stock surged in intraday trading Tuesday after the company beat second-quarter revenue expectations and raised its full-year guidance.

Read More

Zacks Investment Research

Aug 6, 2024

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep